2
Orphan Designations
0 approved, 2 designated
0
FDA Approvals
0
Active Trials
4
Rare Diseases
across 6 areas
0
News (30d)
Quiet
Altamira Therapeutics Inc. is a company with 2 orphan drug designations across 4 rare diseases.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| acute bilirubin encephalopathy | (UDU-stereoisomer of c-UJUun UNU-terminal UkUnhibitor) | Des.TrialAppr. |
| infantile liver failure syndrome 1 | (UDU-stereoisomer of c-UJUun UNU-terminal UkUnhibitor) | Des.TrialAppr. |
| obesity disorder | Betahistine dihydrochloride | Des.TrialAppr. |
| sudden sensorineural hearing loss | (UDU-stereoisomer of c-UJUun UNU-terminal UkUnhibitor) | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
0/4
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
0/4
candidate diseases
0
avg importance: 0
0
affecting portfolio